Premium
Carbohydrate antigen 19‐9‐positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine
Author(s) -
Kato Toshiki,
Hashimoto Yoshihiro,
Okada Shinsuke,
Tozawa Keiichi,
Takahashi Satoru,
Kohri Kenjiro
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01908.x
Subject(s) - medicine , adenocarcinoma , gemcitabine , prostate , prostatectomy , immunohistochemistry , pathological , radical retropubic prostatectomy , prostate specific antigen , urology , metastasis , cisplatin , oncology , pancreatic ductal adenocarcinoma , pathology , prostatic adenocarcinoma , chemotherapy , cancer , pancreatic cancer
We performed a radical retropubic prostatectomy on a 59‐year‐old male patient who was diagnosed with prostatic carcinoma. Pathological findings revealed a ductal adenocarcinoma in the left lobe of the prostate, and a conventional well‐differentiated adenocarcinoma in the right lobe. Immunohistochemistry revealed that CA19‐9 was positive in the ductal adenocarcinoma, and prostate‐specific antigen was positive in the conventional well‐differentiated adenocarcinoma. Since there was an increase in the level of serum CA19‐9, which had decreased postoperatively, along with the appearance of local recurrence and bone metastasis, we treated the patient with cisplatin and gemcitabine. As a result, the level of serum CA19‐9 was normalized and a reduction of the metastatic focus was observed.